Abivax Extends Cash Runway Into Q4 2029 After €767.1 Million Offering
Key Facts
Abivax had €402.4 million of cash, cash equivalents and short-term investments on June 30, 2026. The company added €767.1 million of net proceeds from a public offering completed in early July and projects that the two amounts will fund operations into Q4 2029 under current operating assumptions.
Total operating income rose to €2.5 million from €2.1 million, while the net loss widened to €165.9 million from €100.8 million.
Research and development spending increased to €107.9 million from €77.9 million and represented 75.5% of operating expenses, while net cash used in operating activities rose to €102.5 million from €66.6 million. The offering proceeds extend the period in which the company can fund trials without raising new capital, but faster spending could shorten the projected runway.
Upcoming milestones include Abivax's participation at UEGW in October 2026, a planned new drug application for Obefazimod in ulcerative colitis by the end of 2026, and topline results from the Phase 2b ENHANCE-CD induction trial in mid-2027. Those events will test whether current spending is moving the program toward approval and commercialization.
Latest Updates · 1
- Notable·
Update: Abivax received positive pre-NDA feedback from the U.S. FDA for its lead candidate Obefazimod and strengthened its executive team with the appointment of a new Chief Medical Officer and Chief Technical Officer. Meanwhile, Wedbush adjusted its outlook by lowering the price target for AAVXF to $118, though it remains below the broader consensus target of $156.38.